Allena Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases. Allena's lead program, ALLN-177, is in an ongoing Phase 2 clinical trial in patients with hyperoxaluria. The company's proven approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by reducing toxic metabolites without being absorbed into the bloodstream. Led by a proven management team with deep expertise in protein therapeutic design and development, Allena is committed to bringing new breakthrough treatments to patients with unmet medical needs. Based in Newton, Mass., the company is backed by top-tier venture investors including Frazier Healthcare, Third Rock Ventures, HBM Partners, Bessemer Venture Partners and Pharmstandard International.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/04/14 | $25,000,000 | Series B |
Frazier Healthcare HBM Partners Pharmstandard International Third Rock Ventures | undisclosed |
| 12/09/15 | $53,000,000 | Series C |
Fidelity Investments Frazier Healthcare HBM BioCapital Partner Fund Management Wellington Management Company | undisclosed |
